Literature DB >> 22404487

Detection of antibodies against the non-calcium-dependent epitopes of desmoglein 3 in pemphigus vulgaris and their pathogenic significance.

K Kamiya1, Y Aoyama, Y Shirafuji, T Hamada, S Morizane, K Fujii, K Hisata, K Iwatsuki.   

Abstract

BACKGROUND: Antidesmoglein (anti-Dsg) 3 serum antibody titres are usually correlated with the disease activity of pemphigus vulgaris (PV), but some patients retain high titres even in remission.
OBJECTIVES: The aim of our study was to determine whether anti-Dsg3 antibodies in PV sera recognized calcium (Ca(2+) )-dependent or non-Ca(2+) -dependent epitopes, and to evaluate their pathogenicity.
METHODS: Dsg3 baculoprotein-coated enzyme-linked immunosorbent assay (ELISA) plates were treated with 0.5 mmol L(-1) ethylenediaminetetraacetic acid (EDTA). The binding ability of anti-Dsg3 monoclonal antibodies (mAbs) was analysed. Eight of the 83 patients with PV who were screened had elevated Dsg3 ELISA index values > 00 in remission. The binding ability of these PV sera was analysed. We evaluated the pathogenicity of anti-Dsg3 serum antibodies against the non-Ca(2+) -dependent epitopes using a dissociation assay.
RESULTS: The reactivity of pathogenic anti-Dsg3 mAbs against the Ca(2+) -dependent epitopes diminished markedly in the EDTA-treated ELISA, whereas no such reduction was observed in mAbs against the non-Ca(2+) -dependent epitopes. The sera of all the patients contained antibodies against both Ca(2+) -dependent and non-Ca(2+) -dependent epitopes. In six out of the eight patients, the ratio of antibodies against Ca(2+) -dependent to non-Ca(2+) -dependent epitopes decreased in remission. EDTA-treated Dsg3 baculoproteins adsorbed anti-Dsg3 serum antibodies against the non-Ca(2+) -dependent epitopes, but the remnant PV antibodies retained the ability to induce acantholysis in the dissociation assay.
CONCLUSIONS: We have established an assay to measure indirectly the titres of anti-Dsg3 serum antibodies against the Ca(2+) -dependent epitopes, based on the differences between EDTA-untreated and EDTA-treated ELISA index values, as a routine laboratory test to reflect the pathogenic anti-Dsg3 serum antibody titres more accurately.
© 2012 The Authors. BJD © 2012 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22404487     DOI: 10.1111/j.1365-2133.2012.10929.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

Review 1.  Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.

Authors:  Robert Pollmann; Thomas Schmidt; Rüdiger Eming; Michael Hertl
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 2.  Immune response in pemphigus and beyond: progresses and emerging concepts.

Authors:  Giovanni Di Zenzo; Kyle T Amber; Beyza S Sayar; Eliane J Müller; Luca Borradori
Journal:  Semin Immunopathol       Date:  2015-11-23       Impact factor: 9.623

3.  Evaluation of anti-desmoglein-1 and anti-desmoglein-3 autoantibody titers in pemphigus patients at the time of the initial diagnosis and after clinical remission.

Authors:  Irene Russo; Francesco Paolo De Siena; Andrea Saponeri; Mauro Alaibac
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

Review 4.  Autoimmune Pemphigus: Latest Advances and Emerging Therapies.

Authors:  Yen Loo Lim; Gerome Bohelay; Sho Hanakawa; Philippe Musette; Baptiste Janela
Journal:  Front Mol Biosci       Date:  2022-02-04

5.  Autoantibodies against Desmoglein 1 and 3 in South Tunisian pemphigus.

Authors:  Ameni Jerbi; Hend Hachicha; Sawsan Feki; Olfa Abida; Emna Bahloul; Khadija Sellami; Amina Bouzid; Hamida Turki; Abderrahmen Masmoudi; Hatem Masmoudi
Journal:  Tunis Med       Date:  2021 Octobre

6.  Pemphigus vulgaris autoantibody profiling by proteomic technique.

Authors:  Mina Kalantari-Dehaghi; Grant J Anhalt; Michael J Camilleri; Alex I Chernyavsky; Sookhee Chun; Philip L Felgner; Algis Jasinskas; Kristin M Leiferman; Li Liang; Steve Marchenko; Rie Nakajima-Sasaki; Mark R Pittelkow; John J Zone; Sergei A Grando
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

7.  Short-term clinical and serological follow-up with conventional and conformational anti-desmoglein antibodies in treatment-naïve and previously treated patients with pemphigus vulgaris after receiving rituximab.

Authors:  Hoorieh Alaeen; Roja Toosi; Hamidreza Mahmoudi; Kamran Balighi; Soheil Tavakolpour; Amir Teimoupour; Maryam Daneshpazhooh
Journal:  Int J Womens Dermatol       Date:  2019-06-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.